Drug intelligence / Profile preview

Pheniprazine

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class. It was used as an antidepressant in the 1960s and also for treating schizophrenia and angina pectoris. However, it was discontinued due to liver toxicity and optic neuritis.

Brand names: CatronCavodil
Other names: Phenizinebeta-PhenylisopropylhydrazineDicatron

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on Pheniprazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pheniprazine.

Explore the full profile